Cellular immunotherapy as a therapeutic approach in multiple myeloma. Issue 7 (3rd July 2018)

• Record Type: Journal Article
• Authors: Liegel, Jessica; Avigan, David; Rosenblatt, Jacalyn
• Is Part Of: Expert review of hematology. Volume 11:Issue 7(2018)
• Page Start: 525
• Page End: 536
• Publication Date: 2018-07-03
• Subjects: Myeloma -- vaccine -- T cell -- adoptive therapy -- dendritic cell -- chimeric antigen -- cellular therapy; Hematology -- Periodicals; 616.15005
• DOI: 10.1080/17474086.2018.1483718
• Languages: English
• ISSNs: 1747-4086

Abstract

ABSTRACT: Introduction : Immunotherapy seeks to restore and augment the unique ability of the immune system to recognize and kill malignant cells. This strategy has previously been incorporated into standard of care in myeloma with the use of immunomodulatory drugs and allogeneic transplant. The following review will discuss the rationale for immunotherapy to reverse critical aspects of the immunosuppressive milieu in myeloma and avenues where cellular therapies are now revolutionizing myeloma treatment. Areas covered : A particular focus is outcomes of clinical trials in myeloma published in PubMed database or abstract form using vaccines or adoptive cell transfer: marrow infiltrating lymphocytes, T-cell receptor and chimeric antigen receptor T cells. Expert commentary : Immunotherapy has extraordinary potential in myeloma. Combinations of cellular therapies with immunomodulatory molecules or checkpoint inhibitors are likely to be synergistic and now underway. Future directions include neoantigen or nanoparticle vaccines and further modifications of engineered T cells such as use of dual-antigens, suicide genes or allogeneic cells.